Board of Directors
J. Martin Carroll
Chairman of the Board
Mr. Carroll most recently led Global Strategy and Development for Boehringer Ingelheim GmBH. Prior to that role, he was the President and CEO of US Businesses for Boehringer Ingelheim, overseeing an organization with revenues in the U.S. in excess of $7 billion and over 10,000 employees. His previous experience includes 25 years with Merck & Company, Inc., most recently as Executive Vice President, Customer Marketing and Sales. Mr. Carroll is currently a member of the Board of Directors at Catalent, Inc., TherapeuticsMD, Inc. and Mallinckrodt Pharmaceuticals. Mr. Carroll served in the United States Air Force, and received a Bachelor of Arts degree in Accounting and Economics from the College of the Holy Cross and a Master of Business Administration degree from Babson College.
Mr. Timothy Barberich most recently served as Co-Founder and Chief Executive Officer of Sepracor, Inc. for more than 20 years before it was acquired by Dainippon Sumitomo in 2009. At Sepracor, Barberich grew corporate revenues to $1.3 billion though the successful commercialization and partnering of several products, including Allegra®, Brovana ®, Clarinex®, Lunesta® and Xopenex ®. Before founding Sepracor, Barberich held several senior level marketing and sales positions at Millipore Corporation. Barberich currently serves as a member of the Board of Directors of Frequency Therapeutics, GI Dynamics, Inc., (ASX: GID), Inotek Pharmaceuticals, Inc. (NASDAQ: ITEK), MirImmune, Inc., Neurovance, Inc., Versatem, Inc. (NASDAQ: VSTM) and Tokai Pharmaceuticals. Barberich earned a BS in chemistry from Kings College.
Chief Business Officer, Kiniksa Pharmaceuticals
Mr. Boess brings more than two decades of experience in finance in the biotech and pharmaceutical industries to the board of Inotek. He is currently the Chief Business Officer at Kiniksa Pharmaceuticals, a privately held biotechnology company. He previously served as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company’s acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals, and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China.
Mr. Boess received a Bachelor’s degree and Master’s degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.
Paul G. Howes
Mr. Howes joined the board of Inotek in September of 2008 and also served for five years as the Company's President & CEO. Currently, he serves as the Executive Chairman of ThromboGenics, Inc., and on the board of its Belgian parent company, ThromboGenics NV.
Mr. Howes brings over 25 years of commercial strategy, product development and sales and marketing experience with a significant focus in the field of ophthalmology. Prior to joining Inotek, Mr. Howes was President of the Americas Region for Bausch & Lomb with leadership responsibility for the United States, Canada, Latin America and South America across Bausch & Lomb's Vision Care, Surgical and Pharmaceuticals business segments. During that time, he led a major expansion of the U.S. pharmaceutical business and a highly successful turn-around of the U.S. cataract surgical business. Prior to joining Bausch & Lomb in 2003, Mr. Howes spent the previous 16 years in various senior management roles at Merck & Co. Inc. This experience included roles as Executive Director of Hospital Marketing, Vice President of Sales and Marketing for Specialty Products, President & CEO of the DuPont Merck Pharmaceutical Company and President of Merck Frosst Canada, Inc. Prior to Merck, Mr. Howes spent 11 years at Price Waterhouse Canada.
Mr. Howes is a graduate of Harvard College and earned his MBA from York University in Toronto, Canada. He also serves as Chairman of Prevent Blindness America and on the board of Kish Bancorp.
Mr. Machado was a co-founder of Medivation, Inc. and served as its Chief Business Officer from December 2009 to April 2014 and as its Chief Financial Officer from December 2004 until March 2014. From 1998 to 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company, as Vice President, Chief Financial Officer and General Counsel from 1998 to 2000 and as Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 to 2002, Mr. Machado served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado currently serves on the board of directors of biopharmaceutical companies Chimerix, Inc. (NASDAQ: CMRX), Scynexis, Inc. (NASDAQ: SCYX), Roivant Sciences Ltd., and Armaron Bio Pty. Ltd., where he also serves as chair of the board. Mr. Machado received a JD from Harvard Law School and a BA and BS in German and Economics, respectively, from Santa Clara University.
Gary M. Phillips, MD
Senior Vice President, Chief Strategy Officer, Mallinckrodt Pharmaceuticals
Dr. Phillips has served as Senior Vice President, Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc since October 2013. He was also President of Autoimmune and Rare Diseases at Mallinckrodt from August to December 2014. Gary was Head of Global Health & Healthcare Industries at the World Economic Forum in Geneva from January 2012 to September 2013. He was President of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior) from 2011 to 2012. He served as President of U.S. Surgical and Pharmaceuticals at Bausch & Lomb from 2002 to 2008. Dr. Phillips has also held executive roles at Merck Serono SA (a division of Merck KGaA) from 2008 to 2011, Novartis Corporation from 2000 to 2002, and Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.) from 1999 to 2000. Dr. Phillips was a healthcare strategy managing consultant at Towers Perrin (now Towers Watson & Co) from 1997 to 1999, and practiced as a general medicine clinician/officer in the US Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an MBA from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry with distinction from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license. Currently, he serves on the boards of Aldeyra Therapeutics, Envisia Therapeutics, and Rheon Medical SA.
David P. Southwell
President and Chief Executive Officer
Mr. Southwell joined Inotek in August 2014 as President and Chief Executive Officer. Mr. Southwell brings to Inotek over 20 years of specialty pharmaceuticals and biotechnology experience, including IPOs, follow-on financings, mergers and acquisitions and corporate leadership.
Most recently, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Human Genome Sciences during the approval and launch of the novel biologic treatment for lupus, BenlystaÂ®, and up until its acquisition by Glaxo Smithkline. Prior to his appointment as CFO, he served on the Board of Directors of Human Genome Sciences. Mr. Southwell's career started in investment banking at Lehman Brothers, where among other financing and M&A transactions he led the IPO of Sepracor Inc. He subsequently joined Sepracor as EVP, Chief Financial Officer, a position he held for fourteen years during which time Sepracor raised over $2 billion in equity and convertible security financings, and developed, launched and commercialized two novel medicines for asthma and insomnia. Following his time at Sepracor, he mounted a funded take-private bid for the company with the company's founder, which led to its acquisition by Dainippon Sumitomo in 2009.
Mr. Southwell serves on the boards of PTC Therapeutics and THL Credit, Inc., and on the Board of Overseers of the Tuck School of Business at Dartmouth College. His previous board memberships include Biosphere Medical, Inc. (acquired) as Chairman. He holds an MBA from the Tuck School, and a BA is from Rice University.
Richard N. Spivey, PharmD, PhD
Dr. Spivey is a senior pharmaceutical executive with 30 years of research and development (R&D) experience within large, medium, and small global pharmaceutical companies. He currently serves as a scientific advisor to the Industry and as an Independent Board Director.
Prior to his current role, Dr. Spivey was Senior Vice President and Head of Global Regulatory Affairs at Allergan, a global pharmaceutical and medical device company. Previously, he was Chief Scientific Officer and Head of R&D at Meda AB (following the acquisition of Medpointe Pharmaceuticals, where he served in the same capacity).
Dr. Spivey served in various capacities within global pharmaceutical companies, including Head of Regulatory Affairs at Pharmacia (now Pfizer, Inc.) and Searle (now Pfizer, Inc.). Prior to that, he held progressively more responsible positions within the Regulatory Affairs organizations at Schering Plough (now, Merck, Inc.) and Parke-Davis/Warner-Lambert (now Pfizer, Inc.).
Dr. Spivey received his PharmD from the University of Southern California and his PhD from the College of Pharmacy, University of Minnesota.